stockrow
Friday 6 November 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
33.27
2.91
+9.58%
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) EPS (diluted)
Definium Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$2.06, compared with −$1.54 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.43. Over the past ten years it has ranged from −$3.45 (fiscal 2021) to −$0.11 (fiscal 2016); the current reading is higher than 33% of that period. Definium Therapeutics, Inc. ranks 396th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.06 | — |
| FY2024 | −$1.54 | — |
| FY2023 | −$2.44 | — |
| FY2022 | −$1.84 | — |
| FY2021 | −$3.45 | — |
| FY2020 | −$1.91 | — |
| FY2019 | −$1.56 | — |
| FY2018 | −$2.01 | — |
| FY2016 | −$0.11 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.44 | — |
| Mar 2026 | −$0.71 | — |
| Dec 2025 | −$0.50 | — |
| Sep 2025 | −$0.78 | — |
| 24 more quarters | Free account |
Against its own ten years
Low −$3.45
High −$0.11
Ten-year median
−$1.91
Current reading's percentile
33
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $0.22 |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$0.50 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| DFTX Definium Therapeutics, Inc. | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item